The thymidine kinase/ganciclovir (TK/GCV) cancer gene therapy approach is based on inducing GCV metabolite cytotoxicity in tumor cells expressing the herpes simplex virus TK gene and exposed to GCV. A bystander effect, mediated by gap junctions, accounts for the transfer of toxic metabolites from TK-expressing cells to neighboring cells. It has been proposed that E-cadherin participates in the formation and function of such gap junctions. In this study we investigate the influence of E-cadherin on TK/GCV suicide therapy with a panel of cellular and in vivo models of pancreatic ductal adenocarcinoma. We observed a strong correlation of E-cadherin expression and the TK/GCV bystander effect, associated with the modulation of gap junction communication and connexin expression or localization. Importantly, the co-expression of TK and E-cadherin genes in the adenoviral vector AdTat8TKIE improved TK/GCV cytotoxicity and triggered a potent antitumoral effect, superior to standard AdTat8TK/GCV in MIAPaCa-2 xenografts. The increased expression of E-cadherin resulted in the reduction of the bcl-2 content. Interestingly, the knockdown of bcl-2 sensitized cells to TK/GCV. Thus, we propose that by restoring E-cadherin in pancreatic tumor cells we will improve TK/GCV therapy, both by enhancing the bystander effect and by facilitating the induction of apoptosis.
INTRODUCTION
The herpes simplex virus thymidine kinase gene/ganciclovir prodrug system (TK/GCV) is a well-studied gene-directed prodrug activation approach for the treatment of cancer, presenting promising results against some malignant conditions. 1,2 It consists on the transfer of the TK gene to the tumoral cells, followed by the administration of the nucleoside analogue GCV. TK expression converts GCV to its monophosphate form that later, in turn, is converted by cellular enzymes into GCV triphosphate. The compounds are then incorporated into the genome, triggering the formation of double-strand breaks and, finally, causing cell death by apoptosis. 3, 4 The cytotoxicity of the system is known to be enhanced by the bystander effect when mediated by the transfer of GCV metabolites from the TK-expressing cells to the adjacent TK À cells. Early studies have shown that this phenomenon contributes greatly to the strong antitumoral effect reported in animal models, with complete tumor regression and only 10% of cells expressing TK. 5, 6 The movement of toxic metabolites into neighboring cells takes place through cellular gap junctions and is mediated by connexins. 7, 8 Gaining the capacity to achieve a relevant TK/GCV bystander effect may have important consequences, as it could potentially overcome the requirement for all malignant cells to be transduced to achieve meaningful tumor regression. In such circumstances, TK/GCV therapy would provide relevant antitumoral efficacy, despite the current limitations of vector transduction. Along such lines, it has been shown that the reintroduction of connexins into poor communicating cells can help reestablish gap junction intercellular communication (GJIC) and enhance TK/GCV toxicity. 7, 9, 10 However, the high number of different connexins, types of tissue and tumor expression does not facilitate the identification of an optimal candidate.
To form gap junctions, the membranes of the interacting cells must come closer together and the connexon aggregate must be matched in the opposed cell membrane. There is growing evidence that the expression of cell adhesion molecules, for example, cadherins, can have a marked influence on gap junction assembly and communication. [11] [12] [13] [14] [15] Thus, we hypothesized that the status of E-cadherin in tumoral cells might be influencing the bystander effect of the TK/GCV system and, therefore, the often silenced expression of E-cadherin in tumoral tissue might be limiting the success of TK/GCV therapy.
In this study we developed cellular models with different levels of E-cadherin expression and studied the TK/GCV bystander effect. We found a correlation between E-cadherin cellular content and the bystander effect that is associated with gap junction communication and the expression and localization of connexins. Moreover, we showed that the co-expression of TK enzyme and E-cadherin leads to enhanced TK/GCV cytotoxicity in different models of pancreatic ductal adenocarcinoma. Interestingly, xenograft treatment with recombinant adenovirus co-expressing E-cadherin and TK, followed by GCV administration, resulted in a potent level of antitumor activity, significantly higher than in standard AdTK/GCV therapy.
RESULTS

E-cadherin influences the TK/GCV bystander effect
To assess the involvement of E-cadherin in the bystander effect of TK/ GCV suicide therapy, we identified human pancreatic ductal adenocarcinoma cell lines with different levels of E-cadherin content and generated cellular models of E-cadherin knockdown and E-cadherin overexpression. First, the expression of E-cadherin was examined in NP-9, NP-18, BxPC-3, PANC-1 and MIA PaCa-2 by western blot analysis. PANC-1, BxPC-3 and NP-18 expressed epithelial cadherin, although lower levels were detected in the NP-18 cells. However, no E-cadherin expression was detected in MIA PaCa-2 and NP-9 cells (Figure 1a ). Next we used lentiviral shRNA knockdown approaches to deplete endogenous E-cadherin expression in NP-18, PANC-1 and BxPC-3 cells. Protein immunoblotting showed a reduction in E-cadherin abundance in NP-18 shEcad, PANC-1 shEcad and BxPC-3 shEcad (Figure 1b ). In contrast, no effect was observed in any of the cell lines transduced with viral vectors expressing a control shRNA (data not shown). Cellular models of overexpression were generated by transducing NP-18 and MIA PaCa-2 cells with retroviral vectors carrying the human E-cadherin gene. Western blot analysis confirmed an increase of E-cadherin levels in NP-18 Ecad cells, compared with control cells. Expression of E-cadherin was detected in MIA PaCa-2 Ecad and was localized in the plasma membrane (Figures 1c,d) .
To determine whether the content of E-cadherin in tumoral cells exerts an effect on the bystander effect of the TK/GCV system, we transduced the pancreatic cell lines with different E-cadherin levels described above with the recombinant adenoviral vector AdTK at a multiplicity of infection (MOI) corresponding to IC 80 , and designated as TK + cells. Cocultures of 50% TK + cells and 50% TK À cells were established at high confluence and treated with GCV (10 mg ml À1 ) for 3 days. Cell survival was assessed by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and the percentage of cell viability with respect to phosphate-buffered saline (PBS)-treated cells was calculated. The percentage of cell survival in the cocultures derived from the three cell lines with knockdown E-cadherin was significantly higher than in the control shRNA knockdown cocultures ( Figure 2a ). In contrast, decreased viability of the cocultures was observed in E-cadherin-overexpressing cells (Figure 2b ). Although a tendency to present a similar behavior was observed in the 100% cultures, no significant differences in viability were observed. The results suggest that E-cadherin participates in the TK/GCV bystander effect.
E-cadherin content affects gap junction intercellular communication
It is well documented that the TK/GCV bystander effect is mediated by the transfer of phosphorylated GCV from TK + cells to neighboring cells through gap junctions. To determine whether E-cadherin is involved in GJIC, we performed quantitative gap junction communication functional assays in the different cellular models that showed an E-cadherin-associated TK/GCV bystander effect. The cells were loaded with the membrane-permeable dye calcein AM (donor), mixed with Dil-labeled cells (acceptor) and cocultured at a ratio 1:1 or 1:4 for 2-6 h. At the end of the period we detected the presence of a third, double-stained population (coupled cells). The percentage of coupled cells found, quantified by flow cytometry analysis, was considered an indicator of the degree of GJIC and was expressed as a fold-change with respect to the corresponding control cell lines. As shown in Figure 3 , decreased GJIC effect was detected in the three E-cadherin knockdown cell lines, whereas GJIC was increased in E-cadherinoverexpressing cells (Figures 3a,b) . The results indicate that E-cadherin participates in the GJIC of pancreatic cancer cells.
E-cadherin affects connexin expression and cellular localization
To understand the mechanism underlying the modulation of GJIC by E-cadherin, we characterized the expression of the structural proteins connexins constituting the gap junction channels for the different cellular models. In particular, the study centered on the expression analysis of two major connexins found in the pancreas; Cx26 and Cx43. Immunoblot analysis showed decreased expression of Cx26 in shEcad NP-18 and PANC-1 cells, but not in BxPC-3 E-cadherin knockdown cells. We also detected a decrease in the Cx43 content of the shEcad cell lines NP-18 and BxPC-3 ( Figure 4a ). Conversely, an increase of both Cx26 and Cx43 was observed in NP-18 E-cadherinoverexpressing cells. However, no changes in Cx26 levels were observed in MIA PaCa-2 E-cad-expressing cells. Neither were any changes observed in the Cx43 content of non-Cx43-expressing cells E-cadherin enhances TK/GCV antitumoral therapy L Garcia-Rodríguez et al PANC-1 and MIA PaCa-2 cells (Figure 4a ). The data indicate that the expression of Cx43 is associated to variations in the cellular content of E-cadherin. However, changes in the expression levels of Cx26 were found to be dependent on the cellular context. To further corroborate the influence of E-cadherin content on connexin expression, we performed similar studies to the ones described above on RWP-1 and A549 cells. In E-cadherin knockdown RWP-1 cells a reduction in both Cx43 and Cx26 content was observed, whereas in shEcad A459 cells a reduction in one Cx43 isoform was detected but no changes in Cx26 were appreciated (Supplementary Figure S1) . Next, we determine whether E-cadherin could affect the distribution of Cx26 in cells by analyzing the cellular localization of both E-cadherin and Cx26 in MIA PaCa-2 Ecad and MIA PaCa-2 control cells. E-cadherin immunostaining partially colocalized with the plasma membrane marker Na + /K + -ATPase in the contact areas of BxPC-3 and NP-18 cells that endogenously express E-cadherin and Cx26 (Supplementary Figure  S2) . However, in MIA PaCa-2 control cells Cx26 was only visualized in the cytoplasm. In contrast, in MIA PaCa-2 Ecad cells, Cx26 showed a punctate staining that partially colocalized with the Na + /K + -ATPase marker at the cell membrane, where it was in contact with adjacent cells (Figure 4b ). The results indicate that E-cadherin could participate in relocalizing Cx26 within the cell.
E-cadherin overexpression improves the cytotoxic efficacy of the TK/GCV system We investigated whether an increase in E-cadherin cellular content could enhance the cytotoxicity of the TK/GCV system. To such end, we generated a recombinant adenovirus, AdTat8TKIE, that co-expresses both, a modified TK, previously shown to have enhanced cytotoxicity, 16 and human E-cadherin, and a control virus, AdTat8TK, which only expresses the modified TK gene (Figure 5a ). To confirm the functionality of the viruses, we transduced NP-18, BxPC-3, PANC-1, MIA PaCa-2 and NP-9 pancreatic ductal adenocarcinoma cell lines with different doses of AdTat8TKIE or AdTat8TK, and analyzed E-cadherin expression after 48 h. Immunoblot detection revealed E-cadherin overexpression in all the cell lines transduced with the AdTat8TKIE virus ( Figure 5b ). All said cell lines were also found sensitive to treatment with GCV (data not shown). We next evaluated the cytotoxic response of the AdTat8TKIE/GCV system and compared it to that of the control AdTat8TK/GCV. The five pancreatic cancer cell lines were exposed to increasing viral doses (from 0.05 to 10 MOI) of the two viruses, in either the presence or the absence of GCV (10 mg ml À1 ), and cell viability was evaluated after 3 days by MTT assay. We observed a statistically significant increase in cytotoxicity in those cultures treated with the AdTat8TKIE/ GCV system, as compared with those treated with AdTat8TK/GCV ( Figure 5c ).
It has been proposed that E-cadherin overexpression results in Bcl-2 downregulation and sensitizes tumor cells to etoposide chemotherapy. 17 To evaluate the potential contribution of Bcl-2 in AdTat8TKIE/ GCV-mediated cytotoxicity, we analyzed the Bcl-2 content of AdTat8TKIE MIA PaCa-2-transduced cultures. Mock-infected cultures showed Bcl-2 expression in MIA PaCa-2 cells. Interestingly, Bcl-2 expression was significantly reduced after AdTat8TKIE transduction ( Figure 6a ). Treatment of AdTat8TKIE MIA PaCa-2-transduced cultures with GCV for 3 days showed increased active caspase-3 when compared with AdTat8TK MIA PaCa-2 cultures indicative of enhanced apoptosis (Figure 6b ). To investigate whether Bcl-2 could be mediating TK/GCV sensitivity, we transfected HEK293 cells that endogenously express Bcl-2 with pTat8TK-shBcl-2 knockdown vector (Supplementary Figure S3) , control pTat8TK-shCt or pTat8TK plasmid, and then exposed them to different concentrations of GCV ( Figure 6c ). As can be observed, Bcl-2 knockdown resulted in increased sensitivity to Tat8TK/GCV cytotoxicity. GCV IC 50 values: 7.36 ± 3.81 mg ml À1 pTat8TK, 24.44 ± 10.22 mg ml À1 pTat8TK-shCt and 0.15±0.09 mg ml À1 pTat8TK-shBcl-2.
AdTat8TKIE/GCV treatment presents a more potent antitumoral effect than AdTat8TK/GCV To show whether the enhanced in vitro cytotoxicity of AdTat8TKIE/ GCV treatment translated to an improvement in antitumoral response, we injected MIA PaCa-2 xenograft tumors with 5.2Â10 7 PFU per tumor of AdTat8TK, AdTat8TKIE or an equivalent volume of saline solution for the control group. After 2 days, three of the five groups of animals received three intraperitoneal injections of GCV (100 mg kg À1 ) on 3 consecutive days. The same protocol was then applied again, and two additional rounds of 3 days of GCV were administered. As can be seen in Figure 7a , in the three control groups tumor volume increased 5-to 7-fold over a period of 28 days. In contrast, in the groups treated with either AdTat8TK or AdTat8TKIE and GCV, there was a significant delay in tumor progression. Specifically, in the AdTat8TK/GCV-treated mice, tumor volume increased threefold, whereas in the AdTat8TKIE/GCV-treated animals tumor volume increased only twofold over the same period (AdTat8TK/GCV versus AdTat8TKIE/GCV: Po0.001; Figure 7a ). In the AdTat8TKIE/GCV group 22% of tumors were smaller in size than they were at the outset. The strongest tumor response was observed in the animals that received AdTat8TKIE/GCV at 23 days after inoculation, of which 55% of tumors were found to have lower volume than they initially had (Figure 7b ). This enhanced response might be the consequence of the expression of E-cadherin in tumors with silenced endogenous E-cadherin. In fact, an immunohistochemical analysis of E-cadherin expression in the AdTat8TKIE-injected tumors revealed strong immunoreactivity in the injected area, with E-cadherin nicely expressed in the plasma membrane of tumoral cells (Figure 7c ).
Overall the data show that AdTat8TKIE/GCV therapy has greater antitumor efficacy than AdTat8TK/GCV.
DISCUSSION
In this study, we identify E-cadherin as a new molecule involved in the bystander effect of the TK/GCV system and show that the overexpression, or restoration, of E-cadherin in pancreatic cancer cells enhances both cellular sensitivity to TK/GCV suicide therapy and antitumoral efficacy.
The central role of E-cadherin in modulating the response to a variety of different antitumoral therapies, such as, EGFR-targeted treatment, 18, 19 or the chemotherapeutic agents taxol and etoposide, 17, 20 has been shown. However, the ability of E-cadherin to enhance TK/GCV cytotoxicity is reported for the first time in this study. Our study data show that reestablishing E-cadherin levels will sensitize tumor cells to the therapy. According to our study data, said effect could be mediated by at least two independent mechanisms: (1) E-cadherin enhances the bystander effect of the system, contributing to the spreading of active metabolites; (2) E-cadherin reduces Bcl-2 content, thus facilitating the apoptotic cell death of tumor cells.
It has been clearly established that the bystander effect of the TK/GCV system occurs as a consequence of the movement of GCV metabolites from TK-expressing cells to neighboring cells through gap junction intercellular channels. In this study, we observed that the content of E-cadherin in a cell also influences the TK/GCV bystander effect, associated with changes in gap junction traffic and in the levels or subcellular localization of particular connexins. It would not be surprising then to find that E-cadherin participates in such effects, as it has previously been suggested that cell-cell contact favors connexon docking and clustering, thus contributing to gap junction formation. 21, 22 Additional studies supporting this relationship between E-cadherin and connexins are those showing (1) the colocalization of connexins and cadherins in the same intracellular compartments before the formation of both gap and adherens junctions 23 and (2) the movement of connexin or connexin hemichannels from ER/Golgi compartments to the plasma membrane, through actin cables or microtubule architecture, after the establishment of cadherin junctions. 13, 15 However, the mechanism by which changes in the E-cadherin content are associated to alterations in endogenous connexin levels remains unclear. It could be speculated that E-cadherin expression facilitates Cx transport to the plasma membrane and thus results in a stabilizing effect that minimizes Cx internalization and degradation by lysosomes and proteasomes. 24 In contrast, as shown by E-cadherin knockdown experiments, the lack of adherens junction formation will render connexins more susceptible to degradation.
On the other hand, we have observed a relationship between E-cadherin expression and increased TK/GCV sensitivity in our studies. This effect could be mediated by the induced decrease in Bcl-2 content after E-cadherin expression facilitating apoptotic cell death. In fact, increased sensitivity to TK/GCV and elevated levels of active caspase-3 were observed after Bcl-2 knockdown. Along similar lines, other authors have already shown that the expression of E-cadherin increased drug-induced apoptosis. 17, 20 Interestingly, such increased TK/GCV sensitivity correlated with an enhanced antitumoral response. In fact, although a reduction in tumor progression was observed in both AdTat8TK/GCV-and AdTat8TKIE/GCV-treated mice, the enhancement of the response observed in the E-cadherin group was found to be statistically significantly greater. Moreover, at E-cadherin enhances TK/GCV antitumoral therapy L Garcia-Rodríguez et al day twenty-three, 55% of the tumors of the mice treated with AdTat8TKIE/GCV presented smaller volumes than at the time of starting treatment. The results indicate that the restoration of E-cadherin expression triggers an important increase in the antitumoral efficacy of the TK/GCV system. The administration of AdTat8TKIE adenovirus resulted in extensive E-cadherin expression in the parenchymal tumor cells of the transduced area, which could facilitate the action of AdTat8TKIE/GCV therapy, both by amplifying cell death through the establishment of intercellular gap junctions, mediating a TK bystander effect between the different cell types in the tumor, 4, 25 and by the increased TK/GCV sensitization of transduced cells. Despite the initially positive response, after day 26 the tumors started to grow again, probably because of the limited transduction of the adenoviruses. Additional viral injections, or the use of replicative competent adenovirus, might offset this. Moreover, the reestablishment of E-cadherin function could also be achieved by treating tumors with demethylating or deacetylating drugs. In this respect, the observation of E-cadherin promoter hypermethylation in preneoplasic lesions (intraductal papillary mucinous neoplasms), pancreatic ductal adenocarcinoma samples and derived lymph node metastases, 26, 27 as well as in the undifferentiated pancreatic cancer cell line MIA PaCa-2, suggests that promoter hypermethylation could be a mechanism of E-cadherin gene silencing for a subset of such cancers. 28 Recently it has been shown that the silencing of E-cadherin expression in highly metastatic cells is mediated by a transcriptional repressor complex containing Snail and histone deacetylases 1 and 2. 29 Although E-cadherin has been prominently studied for its role in tumorigenesis, evidencing that the loss of E-cadherin is a critical initiation step in the epithelial-to-mesenchymal transition associated with the invasiveness of tumors, metastatic dissemination and a poor prognosis for several different types of tumor, 30 there are increasing reports of its contribution to the effectiveness of antitumoral therapies. 17, 19, 20, 31 Moreover, E-cadherin has been proposed as a biomarker for therapies, such as EGFR tyrosine kinase activity inhibitors or other molecules interfering with EGFR signaling. 18, 32 Our study data also suggest that E-cadherin expression could be a clinically relevant biomarker for TK/GCV therapy. 
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In conclusion, this study shows for the first time that E-cadherin is a contributing factor to TK/GCV bystander killing and that E-cadherin expression sensitizes tumor cells to TK/GCV cytotoxicity through a Bcl-2-dependent mechanism. Altogether these effects result in an enhanced TK/GCV antitumoral response in pancreatic cancer models. Our findings provide the rationale for the development of more efficient TK/GCV gene therapy approaches to the treatment of pancreatic cancer. The expression cassette encoding the shRNA specific for Bcl-2 or against a nontarget RNA was cloned downstream of the Tat8TK in an inverted orientation to prevent transcriptional interference. Dose-response analysis of GCV in HEK293 cells transfected with pTat8TK, pTat8TK-shCt, pTat8TK-shBcl-2 or mock transfected and treated with GCV for 3 days at the indicated doses.
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MATERIALS AND METHODS
Cell lines and cell culture
The human pancreatic adenocarcinoma cell lines MIA PaCa-2, PANC-1 and BxPC-3, and the human lung cancer cell line A549 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). NP-18, NP-9 and RWP-1 cells were derived from human pancreatic adenocarcinoma biopsies and perpetuated as xenografts in nude mice. 33 Cells were maintained in Dulbecco's modified Eagle's medium (MIA PaCa-2, PANC-1, BxPC-3, NP-9, RWP-1 and A549) or in RPMI 1640 medium (NP-18) (Gibco BRLInvitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum, penicillin (100 mg ml À1 ) and streptomycin (100 mg ml À1 ) (Gibco BRL), and kept at 37 1C in a humidified atmosphere containing 5% CO 2 .
Generation of cell lines expressing shRNA against E-cadherin Lentiviral particles were generated by calcium-phosphate DNA precipitation transfection of vectors pVSV-G (10 mg), pCMVD8.91 (15 mg) and pLKO.1-shRNAEcad (MISSION SHGLYC-TRCN0000039666; Sigma-Aldrich, St Louis, MI, USA) or pLKO.1-shControl (MISSION SHC002; Sigma-Aldrich) (10 mg) into HEK293T cells (ATCC). At 24 and 48 h the viral supernatant was collected, centrifuged at 2500 r.p.m. for 5 min and passed through 0.45 mm filters. The vector was concentrated by ultracentrifugation in a 4% sucrose buffer and used for transduction. NP-18, BxPC-3, PANC-1, RWP-1 and A549 cells, expressing either shRNA targeting E-cadherin (shEcad) or control shRNA (shCt), were generated by lentiviral transduction with 50-200 ml of the viral stock shEcad or shCt for 2 h at 2500 r.p.m. at 37 1C overnight. At 24 h after transduction, cells were selected in 0.5 mg ml À1 puromycin (Sigma-Aldrich) for 3 days. The resistant clones were pooled, assayed for expression of E-cadherin and used for subsequent experiments.
Generation of cell lines expressing exogenous human E-cadherin pBabeEcad retroviral vector was obtained by inserting the 2.8 kb E-cadherin cDNA into the NcoI/HindIII restriction sites of the pBabe backbone. The integrity of the sequence was determined by DNA sequencing. Retroviral particles were generated by calcium-phosphate DNA precipitation transfection of retroviral vectors pBabeEcad or pBabePuro into the Phoenix amphotropic packaging cell line (ATCC). After 48 h the viral supernatant was collected, passed through 0.45 mm filters and used for transduction.
NP-18 and MIA PaCa-2 cells overexpressing human E-cadherin or control cells were obtained by three consecutive rounds of retroviral transduction with 2 ml of either RvpBabeEcad or RvpBabePuro virus-containing media in the presence of 8 mg ml À1 polybrene (Sigma-Aldrich) for 16 h at 37 1C. At 48 h after the third transduction, cells were selected in either 0.5 or 2 mg ml À1 puromycin (Sigma-Aldrich) for 7 days. Resistant clones were pooled, assayed for E-cadherin expression and used for subsequent experiments.
Generation of AdTat8TK and AdTat8TKIE recombinant adenoviruses
The AdTat8TK recombinant adenovirus was generated by inserting the 1.2 kb sequence of the Tat8TK gene, a modified TK with enhanced cytotoxicity, 16, 34 into the BglII/XhoI sites of the pShuttleCMV plasmid (Addgene, Cambridge, MA, USA). The AdTat8TKIE adenovirus was generated by introducing an IRES element at the XhoI site of the pshuttleCMVTat8TK and the E-cadherin gene at the EcoRV site. Next, homologous recombination of the resulting pShuttle vectors with the adenoviral genome was carried out as previously described. 35 Viral particles were obtained and propagated in HEK293 cells and purified by CsCl banding. 36 Physical particle concentration (vp per ml) was determined by optical density reading (OD 250 ), whereas transduction units (Tu per ml) were determined by hexon protein staining. 37 E-cadherin enhances TK/GCV antitumoral therapy L Garcia-Rodríguez et al
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Generation of pU6-shBcl-2, pTat8TK-shBcl-2, pU6-shCt and pTat8TK-shCt plasmids
Two complementary oligonucleotides containing a SalI sticky end, a 21 bp sequence corresponding to base 433-453 of Bcl-2 cDNA (accession number: M14745), a 6 bp linker region corresponding to a HindIII restriction site, the reverse complement of the 21 bp sequence of Bcl-2 cDNA, a termination signal for RNA pol III and a XbaI sticky end were synthesized (Sigma-Genosys, The Woodlands, TX, USA). The oligonucleotides were annealed and cloned into SalI/XbaI-digested pU6 vector, as previously described. 38 The expression cassette for the fusion protein Tat8TK 16 was cloned in a pShuttle-CMV plasmid (Addgene), between the Bgl II and Sal I restriction sites. The U6 promoter and the region encoding the shRNA against Bcl-2 or an shRNA against a nontarget sequence (shCt) 39 were cloned downstream of the Tat8TK expression cassette, in an inverse orientation, at the NotI HindIII sites. 
Western blot analysis
Immunofluorescence analysis
Acetone-fixed cells were blocked with 5% nonfat milk in PBS for 2 h at room temperature, then incubated for 2 h at room temperature with anti-E-cadherin or anti-Cx26 antibodies. After washing with PBS, secondary anti-mouse IgG-Alexa 555 (Molecular Probes, Eugene, OR, USA) was applied for 1 h at room temperature. The nuclei were counterstained with 4¢,6¢-diamidino-2-phenylindole (Sigma-Aldrich) for 30 s. Coverslips were mounted onto glass slides with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA) and visualized on a Leica DMR microscope (Leica Microsystems, Wetzlar, Germany). In co-immunofluorescence confocal studies with Na + /K + -ATPase, after detection of E-cadherin or Cx26, coverslips were incubated for 2 h at room temperature with anti-Na + /K + -ATPase-488 (catalog no. 16-243, UpstateMillipore, Temecula, CA, USA) in PBS. Fluorescence was analyzed on an inverted Leica TCS SP5 confocal scanning laser microscope (Leica) with a Â63 lens. The double fluorescence images were acquired in sequential mode, using the 488-nm line of the argon laser (Alexa 488) and a 633-nm helium-neon laser (Alexa 555), and correspond to one optical section of 1 mm depth. Laser intensity and detector sensitivity were set for the most intensely stained sample, and all other images were captured at the same settings. Omission of the primary antibody resulted in no signal. The images were processed by EMBL ImageJ software (NIH, Bethesda, MD, USA).
Gap junction functional assay
The gap junction functional assay was based on the protocol described by Kapoor et al. 41 with slight modifications. Briefly, donor and recipient cell populations were differentially labeled for 30 min at 37 1C with the gap junction-permeable dye, calcein AM (50 nM; Molecular Probes) or lipophilic dye, DiI (9 mM; Molecular Probes), in complete medium. The donor cells were trypsinized and added to acceptor cells at a donor/acceptor ratio of 1:1 or 1:4 for 2-6 h at 37 1C, depending on the cell line. The density of the cells plated was sufficient to permit cell-cell contact. Cocultures were then collected by trypsinization, resuspended in PBS and subjected to fluorescence-activated cell sorting analysis. Cells were analyzed for the presence of calcein (green fluorescence), DiI (red fluorescence) or both by flow-cytometry (FACScan; Becton Dickinson, Franklin Lakes, NJ, USA). The total number of events counted was 10 000.
TK/GCV bystander effect studies
The TK/GCV bystander effect was measured by determining the viability of a mixed cell population, composed of different percentages of TK + (100 or 50%) and TK À (0 or 50%) cells, cultured for 3 days, in the presence or absence of GCV (10 mg ml À1 , Cymevene; Roche, Madrid, Spain). Cell viability was estimated by an MTT assay (Roche Molecular Biochemicals, Mannheim, Germany), performed in accordance with the manufacturer's instructions.
The TK + cells were generated 24 h before establishing the cocultures by transduction with the recombinant adenovirus expressing the herpes simplex virus thymidine-kinase (AdTK). 42 
Dose-response curves
Dose-response curves were constructed for NP-18, BxPC-3, PANC-1, MIAPaca-2 and NP-9 transduced with either AdTat8TK or AdTat8TKIE and cultured with 10 mg ml À1 GCV for 3 days. Cell viability was measured by an MTT colorimetric assay.
HEK293 subconfluent cultures were transfected with 10 mg pTat8TK, pTat8TK-shCt or pTat8TK-shBcl-2 by calcium phosphate precipitation. At 2 days after transfection, GCV treatment was initiated at the indicated doses and 3 days later viability was measured by an MTT assay.
Immunohistochemistry
Paraffin-embedded samples were prepared from xenografted tumors. Sections (5 mm thick) were submitted to standard deparaffin processing and treated with 10 mM citrate buffer (pH 6.0) for antigen retrieval. Sections were then incubated with an anti-E-cadherin (catalog no. 610181; BD Transduction Laboratories) for 16 h at 4 1C. Bound antibodies were detected with biotinylated secondary antibody, streptavidin-peroxidase complex and diaminobenzidine as the substrate, according to the manufacturer's instructions (DakoCytomation LSAB Plus System-HRP; Dako, Zug, Switzerland). Sections were counterstained with Mayer's hematoxylin and mounted in DPX (Fluka-Sigma, St Louis, MI, USA). Images were captured with a microscope (Leica DMR) and digital camera (Leica DC 500; Leica Microsystems) and processed by Leica Image Manager (IM).
Tumor growth curves
MIA PaCa-2 cells (2.5Â10 6 ), embedded in Matrigel (BD Biosciences), were injected subcutaneously into each posterior flank of BALB/c nude mice (Charles River France, Lyon, France). Tumors were measured three times a week and their volume was calculated by the formula V (mm 3 )¼larger diameter (mm)Âsmaller diameter 2 (mm 2 )/2. Treatment was initiated when tumors achieved a mean volume of 60 mm 3 . All animal procedures met the guidelines of European Community Directive 86/609/EEC, and were approved by the local ethical committee.
Statistical analysis
The results were expressed as mean ± s.e.m. The Mann-Whitney nonparametric test (two tailed) was used for the descriptive statistical analysis of the in vitro studies, performed with SPSS software (Systat Software Inc., Chicago, IL, USA). Po0.05 was taken as the level of significance.
The in vivo tumor growth analysis was performed with S-PLUS functions. Repeated measurements and tumor location in the mouse were considered nested classification factors. We associated random effect terms with the animal factor, the day of measurement and the site nested in the animal. Hence general linear mixed models 43 were used to estimate the effects of treatment on tumor growth. 44 These models allowed us to analyze both the overall effect and the E-cadherin enhances TK/GCV antitumoral therapy L Garcia-Rodríguez et al effect of each round of treatment. Estimation of the coefficients, and their associated P-values, was based on restricted maximum likelihood. A plot of residual versus fitted values was used to check the assumptions of the model. Variance function structure was used to model the heteroscedasticity of the day-to-day errors. Po0.05 (Bonferroni correction) was considered statistically significant after performing multiple comparisons among treated groups.
